Acrux Bilan de santé

Santé financière contrôle des critères 3/6

Acrux possède un total de capitaux propres de A$3.3M et une dette totale de A$1.5M, ce qui porte son ratio d'endettement à 45.4%. Son actif total et son passif total sont A$9.0M et de A$5.7M.

Informations clés

45.4%

Ratio d'endettement

AU$1.49m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$2.95m
Fonds propres	AU$3.28m
Total du passif	AU$5.69m
Total des actifs	AU$8.96m

Mises à jour récentes de la santé financière

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Sep 21

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

May 20

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Feb 04

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Dec 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ACR ( A$6.0M ) dépassent ses passifs à court terme ( A$3.7M ).

Passif à long terme: Les actifs à court terme de ACR ( A$6.0M ) dépassent ses passifs à long terme ( A$2.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: ACR dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de ACR est passé de 0% à 45.4% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ACR dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ACR dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de croître à un taux historique de 17 % chaque année.

Acrux Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Recent updates

New major risk - Market cap size

Acrux Limited, Annual General Meeting, Nov 21, 2024

New major risk - Financial position

Full year 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines